Godavari Drugs Limited confirmed that trials at its newly installed facility for manufacturing DHDT, an anti-HIV drug intermediate, are nearly complete. The company expects to commence commercial supplies against existing orders shortly.

The update was provided by Mohit Jaju, Whole-time Director and Chief Financial Officer, during the company's 38th Annual General Meeting (AGM). The meeting was held on September 25, 2026, via video conferencing and other audio-visual means. This development marks a significant step in the company's product portfolio expansion within the pharmaceutical intermediates segment.

Meeting proceedings and attendance

The 38th AGM was conducted in compliance with the Companies Act, 2013, and circulars issued by the Ministry of Corporate Affairs and SEBI. A total of 86 members attended the meeting through virtual platforms. The requisite quorum was present, allowing the Chairman to call the meeting to order.

All directors attended the meeting through video conferencing from their respective locations. The board composition included both executive and non-executive members, ensuring comprehensive oversight of the proceedings.

Resolutions passed

Shareholders voted on four key items of business, comprising ordinary and special resolutions. The audited standalone financial statements for the financial year ended March 31, 2026, were adopted without any qualifications or adverse remarks from the auditors.

The following resolutions were put to vote:

1. Adoption of audited standalone financial statements for FY26.
2. Re-appointment of Ghanshyam Jaju as a director retiring by rotation.
3. Ratification of remuneration of ₹40,000 payable to M/s Bharathula & Associates as Cost Auditors for FY27.
4. Alteration of the Main Objects Clause of the Memorandum of Association to include nutraceuticals and dietary supplements.

Strategic expansion into nutraceuticals

A special resolution was passed to alter the company's main objects clause. This amendment allows Godavari Drugs to engage in the manufacture, processing, formulation, purchase, sale, import, export, marketing, and distribution of nutraceuticals, dietary supplements, health supplements, natural extracts, herbal extracts, botanical extracts, standardized plant extracts, food ingredients, food additives, functional foods, and allied products.

This move signals a strategic diversification beyond traditional pharmaceutical intermediates into the growing consumer health and wellness sector. The inclusion of these activities in the main objects clause provides the regulatory framework necessary for future investments and operations in this domain.

What the numbers show

While the AGM focused on governance and strategic updates rather than detailed financial breakdowns, two key operational indicators stand out. First, the proximity of the DHDT facility to commercial production suggests a potential near-term revenue driver, assuming supply chain logistics align with demand. Second, the formal inclusion of nutraceuticals in the object clause indicates a medium-term strategic pivot. Unlike a simple product launch, this legal amendment prepares the corporate structure for broader market entry, implying significant planned capital allocation or partnership opportunities in the consumer health space.

Godavari Drugs has scheduled its 38th Annual General Meeting for September 25, 2026, to seek shareholder approval for entering the nutraceuticals and dietary supplements business. The company has also fixed the book closure period from September 19 to September 25, 2026.

The board previously approved an alteration to the Memorandum of Association (MoA) to authorize this new line of business. The amendment requires a Special Resolution under Section 13 of the Companies Act, 2013. Shareholders will vote via electronic means during the designated e-voting window.

Book Closure and Voting Schedule

The Register of Members and Share Transfer Books will remain closed from September 19, 2026 to September 25, 2026 (both days inclusive). This closure determines the members entitled to vote at the meeting. The cut-off date for ascertaining eligible shareholders is September 18, 2026.

Shareholders holding shares in physical or dematerialized form can cast their votes electronically. For shareholders whose email addresses are not registered with the company or its Registrar and Transfer Agent (CIL Securities Ltd), the AGM notice is accessible on the company website and BSE platform.

Strategic Rationale

The existing main objects clause covers drugs and pharmaceuticals but does not explicitly authorize the proposed nutraceutical segment. This new business is governed under the Food Safety and Standards Act, 2006.

The alteration enables Godavari Drugs to validly carry out domestic and export marketing, third-party contract manufacturing, and own manufacturing of bulk ingredients and formulations in this sector. The change is additive in nature and does not involve discontinuing any existing business activities.

Shareholder Approval Process

The resolution will be placed before members at the 38th AGM, which will be held via Video Conferencing or Other Audio Visual Means. The amendment does not affect the existing rights of members or the nature of their liability.

Upon member approval, the company will file Form MGT-14 with the Registrar of Companies, Telangana, to effectuate the change.